Rigel Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript
(audio in progress) 2026 RBC Healthcare Conference. My name's Kevin Meli, part of the biotech team here, and it's our pleasure today to have Dean Schorno, CFO of Rigel Pharmaceuticals. Dean, take it away.
Great. Thank you, Kevin. Thank you, RBC, for having us at your conference this year and for all of you for your interest in Rigel. Really excited to tell this story today. I'll be making some forward-looking statements, so I'd encourage you to look at our rigel.com site, you'll find our SEC filings. You'll also find our complete corporate deck. I'm going to move through the business fairly quickly today. You can also find a link to our conference call last week, where we announced the in-license of VEPPANU. Really important big news for the business. Also remind you as I talk through today, that this transaction's still subject to HSR clearance.
As we get started, Rigel's transformational growth
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
